Amgen Announces Positive Results At ACC.20/WCC From Phase 3B Study Of Repatha® (Evolocumab) In People Living With HIV Who Have High LDL-Cholesterol

CERT-LatestNews Cybersecurity-Covid-19 ThreatsEconomic ThreatsStrategic

. Study Met Primary Endpoint (Change From Baseline in LDL-C) and All Secondary Endpoints. Repatha is the First PCSK9 Inhibitor to Demonstrate LDL-C Lowering Results in People Living with HIV.

THOUSAND OAKS, Calif. March 28, 2020 /PRNewswire/ — Amgen (NASDAQ: AMGN ) today announced positive results….